Template:Acute cystitis antibiotics/es: Difference between revisions

(Created page with "Template:Antibióticos para cistitis aguda")
 
(Created page with "'''Mujeres, Sin complicaciones''' *Nitrofurantoína ER 100mg BID x 5d, O *TMP/SMX DS (160/800mg) 1 tab BID x 3d (Mujeres) x7días (Hombres), O *Cefalexina 250mg QID x 5d, O *Ciprofloxacino 250mg BID x3d **Evitar el uso de fluorquinolona para el tratamiento de primera línea de infecciones del tracto urinario (ITU) sin complicaciones...")
 
Line 1: Line 1:
<noinclude><languages/></noinclude>
<noinclude><languages/></noinclude>


<div lang="en" dir="ltr" class="mw-content-ltr">
===Ambulatorio===
===Outpatient===
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
'''Mujeres, Sin complicaciones'''
'''Women, Uncomplicated'''
*[[Special:MyLanguage/Nitrofurantoin|Nitrofurantoína]] ER 100mg BID x 5d, O
*[[Special:MyLanguage/Nitrofurantoin|Nitrofurantoin]] ER 100mg BID x 5d, OR
*[[Special:MyLanguage/TMP/SMX|TMP/SMX]] DS (160/800mg) 1 tab BID x 3d (Mujeres) x7días (Hombres), O
*[[Special:MyLanguage/TMP/SMX|TMP/SMX]] DS (160/800mg) 1 tab BID x 3d (Females) x7days (Males), OR
*[[Special:MyLanguage/Cephalexin|Cefalexina]] 250mg QID x 5d, O
*[[Special:MyLanguage/Cephalexin|Cephalexin]] 250mg QID x 5d, OR
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacino]] 250mg BID x3d
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacin]] 250mg BID x3d
**Evitar el uso de fluorquinolona para el tratamiento de primera línea de infecciones del tracto urinario (ITU) sin complicaciones en mujeres.<ref>Choosing Wisely. American Urogynecologic Society. http://www.choosingwisely.org/societies/american-urogynecologic-society</ref>
**Avoid using fluoroquinolone for the first-line treatment of uncomplicated urinary tract infections (UTIs) in women.<ref>Choosing Wisely. American Urogynecologic Society. http://www.choosingwisely.org/societies/american-urogynecologic-society</ref>
*[[Special:MyLanguage/Fosfomycin|Fosfomicina]] 3 g VO una vez
*[[Special:MyLanguage/Fosfomycin|Fosfomycin]] 3 g PO once
**Menor éxito clínico y microbiológico comparado con nitrofurantoína TID por 5 días <ref>Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., … Harbarth, S. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, 319(17), 1781–1789.</ref>
**Lower clinical and microbiologic success compared to nitrofurantoin TID for 5 days <ref>Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., … Harbarth, S. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, 319(17), 1781–1789.</ref>
   
   
'''Women, Complicated'''
'''Mujeres, Complicadas'''
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacin]] 500mg BID x10-14d, OR
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacino]] 500mg BID x10-14d, O
*[[Special:MyLanguage/Cefpodoxime|Cefpodoxime]] 200 mg BID x10-14d
*[[Special:MyLanguage/Cefpodoxime|Cefpodoxima]] 200 mg BID x10-14d
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
'''Mujeres, Sospecha de [[Special:MyLanguage/Urethritis|Uretritis]]'''
'''Women, Concern for [[Special:MyLanguage/Urethritis|Urethritis]]'''
*[[Special:MyLanguage/Ceftriaxone|Ceftriaxona]] 250mg IM x1 Y [[Special:MyLanguage/azithromycin|azitromicina]] 1gm VO x1 Y [[Special:MyLanguage/nitrofurantoin|nitrofurantoína]] ER 100mg BID x5d, O
*[[Special:MyLanguage/Ceftriaxone|Ceftriaxone]] 250mg IM x1 AND [[Special:MyLanguage/azithromycin|azithromycin]] 1gm PO x1 AND [[Special:MyLanguage/nitrofurantoin|nitrofurantoin]] ER 100mg BID x5d, OR
*[[Special:MyLanguage/Levofloxacin|Levofloxacino]] 500mg QD x 14d (cubre patógenos urinarios, [[Special:MyLanguage/GC|GC]], y [[Special:MyLanguage/chlamydia|clamidia]])
*[[Special:MyLanguage/Levofloxacin|Levofloxacin]] 500mg QD x 14d (covers urinary pathogens, [[Special:MyLanguage/GC|GC]], and [[Special:MyLanguage/chlamydia|chlamydia]])
**La resistencia de [[Special:MyLanguage/GC|GC]] a fluorquinolonas está aumentando
**[[Special:MyLanguage/GC|GC]] resistance to fluoroquinolones is increasing
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
'''Hombres'''
'''Men'''
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacino]] 500mg BID x10-14d, O
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacin]] 500mg BID x10-14d, OR
*[[Special:MyLanguage/Cefpodoxime|Cefpodoxima]] 200 mg BID x10-14d
*[[Special:MyLanguage/Cefpodoxime|Cefpodoxime]] 200 mg BID x10-14d
</div>




<div lang="en" dir="ltr" class="mw-content-ltr">
===Opciones de Internación===
===Inpatient Options===
</div>


<div lang="en" dir="ltr" class="mw-content-ltr">
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacino]] 400mg IV q12hr, O
*[[Special:MyLanguage/Ciprofloxacin|Ciprofloxacin]] 400mg IV q12hr, OR
*[[Special:MyLanguage/Ceftriaxone|Ceftriaxona]] 1gm IV QD, O
*[[Special:MyLanguage/Ceftriaxone|Ceftriaxone]] 1gm IV QD, OR
*[[Special:MyLanguage/Cefotaxime|Cefotaxima]] 1-2gm IV q8hr, O
*[[Special:MyLanguage/Cefotaxime|Cefotaxime]] 1-2gm IV q8hr, OR
*[[Special:MyLanguage/Gentamicin|Gentamicina]] 3mg/kg/día dividido q8hr +/- ampicilina 1–2 gm q4hr, O
*[[Special:MyLanguage/Gentamicin|Gentamicin]] 3mg/kg/day divided q8hr +/- ampicillin 1–2 gm q4hr, OR
*[[Special:MyLanguage/Piperacillin/Tazobactam|Piperacilina/Tazobactam]] 3.375 gm IV q6hr, O
*[[Special:MyLanguage/Piperacillin/Tazobactam|Piperacillin/Tazobactam]] 3.375 gm IV q6hr, OR
*[[Special:MyLanguage/Cefepime|Cefepima]] 2gm IV q8hr, O
*[[Special:MyLanguage/Cefepime|Cefepime]] 2gm IV q8hr, OR
*[[Special:MyLanguage/Imipenem|Imipenem]] 500mg IV q8hr
*[[Special:MyLanguage/Imipenem|Imipenem]] 500mg IV q8hr
</div>

Latest revision as of 06:15, 20 January 2026

Other languages:

Ambulatorio

Mujeres, Sin complicaciones

  • Nitrofurantoína ER 100mg BID x 5d, O
  • TMP/SMX DS (160/800mg) 1 tab BID x 3d (Mujeres) x7días (Hombres), O
  • Cefalexina 250mg QID x 5d, O
  • Ciprofloxacino 250mg BID x3d
    • Evitar el uso de fluorquinolona para el tratamiento de primera línea de infecciones del tracto urinario (ITU) sin complicaciones en mujeres.[1]
  • Fosfomicina 3 g VO una vez
    • Menor éxito clínico y microbiológico comparado con nitrofurantoína TID por 5 días [2]

Mujeres, Complicadas

Mujeres, Sospecha de Uretritis

Hombres


Opciones de Internación

  1. ↑ Choosing Wisely. American Urogynecologic Society. http://www.choosingwisely.org/societies/american-urogynecologic-society
  2. ↑ Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., … Harbarth, S. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, 319(17), 1781–1789.
Retrieved from "https://www.wikem.org/w/index.php?title=Template:Acute_cystitis_antibiotics/es&oldid=383286"